SCHEMBL4693991

SCHEMBL4693991

O=C(O)N1CC[C@H](Oc2cnc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3)n2)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 4/20 0.43
PIK3CA P42336 2/20 0.43
PIK3CG P48736 2/20 0.43
PIK3CB P42338 1/20 0.43
CNR1 P21554 5/20 0.42
EGFR P00533 1/20 0.38
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38
CACNB4 O00305 4/20 0.38
CACNA1A O00555 4/20 0.38
CACNA1G O43497 4/20 0.38
CACNG3 O60359 4/20 0.38
CACNA1F O60840 4/20 0.38
CACNA1H O95180 4/20 0.38
CACNB3 P54284 4/20 0.38
CACNA2D1 P54289 4/20 0.38
CACNG7 P62955 4/20 0.38
CACNA1B Q00975 4/20 0.38
CACNA1D Q01668 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14545592 0.93 CNR1 (0.43) PIK3CDPIK3CAPIK3CGPIK3CBCNR1
SCHEMBL4691844 0.91 CNR1 (0.43) PIK3CDPIK3CAPIK3CGPIK3CBCNR1
SCHEMBL14545603 0.81 MET (0.43) CNR1
SCHEMBL5516419 0.80 MAPT (0.40) PIK3CDPIK3CAPIK3CGPIK3CBCNR1
SCHEMBL7105199 0.80 MMP1 (0.47) EGFRHMOX1SPR
SCHEMBL7107806 0.80 MMP1 (0.47) EGFRHMOX1SPR
SCHEMBL14545327 0.78 MCHR1 (0.46) KCNH2MCHR1
SCHEMBL4694942 0.78 CACNB4 (0.53) PIK3CDCKS1BSKP1SKP2CACNB4
SCHEMBL14545566 0.77 ESR1 (0.43) PIK3CDPIK3CAPIK3CGPIK3CBCNR1
SCHEMBL14545335 0.76 ACHE (0.49) KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1871762-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2008-01-02 EP disclosed
WO-2006113704-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-10-26 WO disclosed